Celgenyx
Latest round
- Series A
Last raised
- Oct 2022
Total raised
- $14M
Investors
- 1
About Celgenyx
, dba Celgenyx, operates as a biotechnology company that focuses on the treatment of malignant tumors. The company cooperates with USA in March 2020. The company provides gene technology and cellular immune products. Its R&D platform includes hybridoma antibody technology platform, antibody humanization technology platform and human antibody phage display platform. Hybridoma antibody technology platform develops innovative murine scFv against human tumor antigen.
Who invested in Celgenyx
1 investor across 1 round
See all investors in Celgenyx
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Oct 24, 2022
Amount
$14M
Investors
Questions about Celgenyx
Who invested in Celgenyx?
Celgenyx has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Celgenyx raised?
Celgenyx has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Celgenyx last raise money?
Celgenyx's most recent round on record is a Series A, in Oct 2022.
What does Celgenyx do?
, dba Celgenyx, operates as a biotechnology company that focuses on the treatment of malignant tumors.
Where is Celgenyx headquartered?
Celgenyx is headquartered in Hangzhou, China.
Which VCs invest in companies like Celgenyx?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Celgenyx's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Celgenyx? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.